Thursday, June 18, 2026

No Result

View All Result

Media

No Result

View All Result

Health

Appropriate medication use includes access to state-of-the-art drugs: Nigel Rawson and John Adams in National Newswatch

November 21, 2025

John Adams

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

August 30, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

August 23, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

August 16, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

August 9, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

July 26, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

July 19, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

July 12, 2023

The U.S. outsources control of drug prices to Canada: weird! Richard Owens in the Financial Post

Columns

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

March 1, 2023

Columns

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

January 24, 2023

Can we afford National Pharmacare and do people want it? Jeffrey Simpson for Inside Policy

Columns

PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy

November 23, 2022

Build health care back better: Philip Cross in the Financial Post

Columns

Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post

November 2, 2022

Page 3 of 4 Prev 1 2 3 4 Next

Newsletter Signup

Email Address *

First Name *

Last Name *

*Required Fields

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

Appropriate medication use includes access to state-of-the-art drugs: Nigel Rawson and John Adams in National Newswatch

John Adams

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy

Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post

Top News

Building indigenous business in Canada’s energy economy: Christine Goulais and Karen Restoule for Breakthrough Nation

The economics of terror: Why Canada should explicitly criminalize pay-for-slay programs

Carney wants Canada to become an energy superpower. Where will the money come from?: David Detomasi in The Hub

Multimedia

Building indigenous advantage in Canada’s mining economy

Canada-Australia critical minerals collaboration: Roundtable discussion

Liberalism is in crisis: Michael Bonner and Peter Copeland for Inside Policy Talks

Pratas Island is Beijing’s next pressure point and Washington’s next test: Joe Varner in the National Review

Senior Canadian officials seek to isolate Israel – and Canada’s Jewish community: Alan Kessel for Inside Policy

A separate Alberta would be a poorer Alberta: Trevor Tombe in The Hub

Undoing Charter creep

Canada’s looming electricity crisis

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us